A comparison of multiple sclerosis disease ...
Type de document :
Article dans une revue scientifique
DOI :
PMID :
URL permanente :
Titre :
A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo.
Auteur(s) :
Vermersch, Patrick [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Radue, Ernst-Wilhelm [Auteur]
Putzki, Norman [Auteur]
Ritter, Shannon [Auteur]
Merschhemke, Martin [Auteur]
Freedman Mark, S [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Radue, Ernst-Wilhelm [Auteur]
Putzki, Norman [Auteur]
Ritter, Shannon [Auteur]
Merschhemke, Martin [Auteur]
Freedman Mark, S [Auteur]
Titre de la revue :
Multiple sclerosis journal - experimental, translational and clinical
Nom court de la revue :
Mult Scler J Exp Transl Clin
Numéro :
3
Pagination :
2055217317730096
Date de publication :
2017-01-01
ISSN :
2055-2173
2055-2173
2055-2173
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
BACKGROUND: Cases of higher-than-expected disease activity have been reported following fingolimod discontinuation. OBJECTIVE: The objective of this paper is to assess the risk of substantially higher-than-expected ...
Lire la suite >BACKGROUND: Cases of higher-than-expected disease activity have been reported following fingolimod discontinuation. OBJECTIVE: The objective of this paper is to assess the risk of substantially higher-than-expected disease activity post-study drug discontinuation (SDD) at the individual patient level using data from the Phase III, placebo-controlled FREEDOMS and FREEDOMS II trials. METHODS: Baseline gadolinium-enhancing T1-lesion volumes were used to statistically model the expected level of MRI disease activity post-SDD. Patients exceeding this level were classed asLire moins >
Lire la suite >BACKGROUND: Cases of higher-than-expected disease activity have been reported following fingolimod discontinuation. OBJECTIVE: The objective of this paper is to assess the risk of substantially higher-than-expected disease activity post-study drug discontinuation (SDD) at the individual patient level using data from the Phase III, placebo-controlled FREEDOMS and FREEDOMS II trials. METHODS: Baseline gadolinium-enhancing T1-lesion volumes were used to statistically model the expected level of MRI disease activity post-SDD. Patients exceeding this level were classed asLire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
Inserm
Université de Lille
CHU Lille
Université de Lille
CHU Lille
Équipe(s) de recherche :
Immunity, inflammation and fibrsis in auto and allo-reactivity
Date de dépôt :
2019-03-01T14:09:32Z